SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil Corp is rallying fiercely as escalating geopolitical tensions, particularly concerning the Strait of Hormuz, drive strong momentum and intense community discussion about a massive short and gamma squeeze in this low-float energy stock.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is a hot topic following its Q4 earnings report, which featured increased revenue and substantial contracted commitments, alongside new partnerships with major European carriers like Orange and Telefonica for direct-to-device satellite connectivity. Community sentiment is sharply divided, with strong long-term conviction from bulls who see cutting-edge technology and defense potential, contrasting with bears focused on valuation concerns and past launch delays.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group (GRRR) is trending following strong FY2025 results, featuring record revenue and improved profitability, with the community actively debating its severe undervaluation compared to peers like BBAI. Enthusiasm is further fueled by strategic moves into non-dilutive project financing and new partnerships in the Middle East for large-scale AI infrastructure.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in November 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB is trending sharply lower following its latest earnings report, where strong quarterly results were overshadowed by mixed guidance and news of key leadership departures, fueling community concerns over growth deceleration. Despite the 'brutality' of the drop, investors are divided, with some seeing a long-term buying opportunity and others anticipating further declines to fill a perceived price gap, reflecting broader software sector weakness.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy is trending as escalating Middle East tensions, including Iran's threats to close the Strait of Hormuz and attacks on oil infrastructure, drive expectations for surging crude prices. The community is actively discussing its potential for a substantial rally, drawing parallels to past energy spikes, despite some frustration over its relative performance compared to sector peers and concerns about dilution.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group is trending after its Q3 earnings report, which, despite beating estimates, triggered a sharp after-hours sell-off due to market interpretation of conservative Q4 sales guidance. Community sentiment is split, with many highlighting strong fundamentals and massive AI infrastructure spending as reasons to buy the dip, while others remain cautious given previous volatility and concerns about valuation.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SOFI is trending as CEO Anthony Noto's recent open market share purchase signals strong management confidence, fueling investor optimism and renewed speculation around a potential S&P 500 inclusion. The community widely views this as a significant bullish catalyst, anticipating a positive impact on the stock.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending due to recent milestones, including achieving 100% FAA Means of Compliance acceptance for its Midnight aircraft, which bulls highlight as a significant derisking event for its path to 2026 commercial operations. While Q4 results showed deeper losses, strong liquidity and new defense and Starlink partnerships are fueling community debate, contrasting regulatory progress with continued cash burn in the evolving eVTOL sector.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ouster is trending following its strategic acquisition of StereoLabs, which combines high-resolution digital lidar with AI vision and perception software to establish a unified Physical AI platform. This move, coupled with recent strong quarterly earnings showcasing impressive gross margins and a reinforcing path to profitability, has sparked bullish community discussion regarding the company's leadership in robotics, industrial automation, and autonomous systems.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending due to significant institutional accumulation and growing speculation that its photonic technology is critical for major hyperscalers, validated by the broader industry's embrace of advanced optics for AI data centers. The community is eagerly awaiting substantial commercialization updates and new partnerships expected around the upcoming industry conference.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The clearance allows the clinical-stage biotech firm to move ahead with preparations for a planned Phase 1b registrational study.</li><li>Serina&nbsp;had previously received written feedback from the agency supporting its proposed registrational trial design under an NDA pathway.</li><li>The latest update follows a setback in November 2025, when the FDA placed a clinical hold on the application to initiate clinical trials.</li></ul>Shares of Serina Therapeutics (SER) surged more than 70% in pre-market trading on Thursday after the company announced that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for SER-252, a therapy to treat patients with Parkinson’s disease.SER-252 is an experimental apomorphine-based therapy to provide continuous dopaminergic stimulation, an approach shown to ease levodopa-related motor complications such as dyskinesia in people with Parkinson’s disease.<a href="https://stocktwits.com/symbol/SER">SER stock</a> had surged nearly 35% in after-hours trading on Wednesday.<h2 class="st-heading-2">SER-252: What Next?</h2>The clearance allows the clinical-stage biotech firm to move ahead with preparations for a planned Phase 1b registrational study in patients with advanced Parkinson’s disease. The IND clearance follows extensive regulatory engagement between Serina and the FDA.The company previously received written feedback from the agency supporting its proposed registrational trial design under an NDA pathway.“With FDA alignment on a registrational development strategy under a 505(b)(2) NDA pathway, we believe SER-252 has a clear and efficient path forward toward addressing a significant unmet medical need,” said Steve Ledger, Chief Executive Officer of Serina Therapeutics.The latest update follows a setback in November 2025, when the FDA placed a clinical hold on Serina’s application to initiate clinical trials. That hold was tied to a request for additional information related to an excipient in the drug’s formulation, a non-active substance included in a drug formulation alongside the active ingredient. Serina emphasized that the FDA’s concerns did not involve SER-252’s active drug substance or its proposed mechanism of action.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bearish’ a day earlier, accompanied by ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/SER_jpg_f485987591.webp" alt="SER.jpg" width="927" height="114"><figcaption>SER's Sentiment Meter and Message Volumes in Premarket on Jan. 29, 2026 | Source: Stocktwits</figcaption></figure>One bullish user said the stock price could double with good volumes.<stembedurl>https://stocktwits.com/Targeted_Trading/message/643250368</stembedurl>Another user simply said “massive news”, and the stock could climb to $8. It is currently around $4.<stembedurl>https://stocktwits.com/madape/message/643249925</stembedurl>SER shares have shed more than 40% in the past year, though its year-to-date gains are over 25%.Read also: <a href="http://stocktwits.com/news-articles/markets/equity/nasdaq-sp500-futures-higher-meta-tsla-ser-mp-crml-stocks-to-watch/cmyidGCR4KJ">Nasdaq, S&amp;P 500 Futures Climb Ahead Of Apple Earnings: Why META, TSLA, MP, CRML, SER Are On Traders' Radar Today</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

A candlestick chart can be seen in a trading platform on a smartphone. Top U.S. firms announced record buybacks this year. (Photo by Silas Stein/picture alliance via Getty Images)

Why Did SER Stock Surge Over 70% In Pre-Market Today?

The U.S. Food and Drug Administration cleared its Investigational New Drug application for SER-252, a therapy to treat patients with Parkinson’s disease.

SER Stock Surges Over 70% Pre-Market After FDA Clears Path For Parkinson’s Therapy

Equity

<ul class="summary-bullets"><li>Wall Street weighed heavy earnings and lingering government shutdown concerns.</li><li>Meta’s upbeat outlook offset Microsoft’s cloud slowdown, shifting focus to Apple’s earnings later today.</li><li>Commodities surged, with gold and silver hitting fresh record highs.</li></ul>U.S. stock futures were higher early Thursday as investors parsed the earnings report from the first of the “Magnificent Seven” companies (Meta, Microsoft, and Tesla), with the focus shifting to Apple, which reports earnings later today.&nbsp;As of 3:00 a.m. ET on Thursday, Nasdaq futures were up 0.4%, S&amp;P 500 futures gained 0.3%, while the Dow and Russell 2000 futures were flat.&nbsp;&nbsp;Meanwhile, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, remained ‘extremely bearish’, amid high message volumes.&nbsp;Precious metals continued to notch fresh records, with gold surging near $5600 and silver past $120.&nbsp;<a href="https://stocktwits.com/symbol/GLD/">SPDR Gold Shares ETF (GLD)</a> was the top trending ticker on Stocktwits at the time of writing. The&nbsp;<a href="https://stocktwits.com/symbol/SLV">iShares Silver Trust (SLV)</a> also saw retail sentiment remaining in the ‘extremely bullish’ territory, with ‘extremely high’ levels of chatter. Among base metals, copper prices too have surged 9% this month.Trending Stocks To WatchApple (AAPL): Investors will be watching for its earnings report after the market closes, with an eye on iPhone demand commentary and updates to its AI roadmap.Western Digital (WDC),&nbsp;SanDisk (SNDK): Watch out for these data storage giants as they report earnings today.Meta Platforms (META), Microsoft (MSFT):&nbsp;Meta stock surged in after-hours, driven by a strong sales forecast and a $100-billion AI investment plan. On the other hand, Microsoft tumbled due to slowing cloud growth and soft margin guidance.Tesla (TSLA): CEO Elon Musk confirmed plans to discontinue two EV models as it pivots to robotics. Tesla has also warned that capital expenditures could exceed $20 billion in 2026.Critical Minerals (MP, UAMY, TMC, USAR, CRML): U.S. miner stocks were under pressure amid reports that the Trump administration was considering shelving plans for minimum price floors. MP Materials was one of the first companies to&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-mp-uamy-tmc-usar-crml-stocks-dip-after-hours-today/cmyLvl0R40w">state</a> that the news was “inaccurate.”&nbsp;Carvana (CVNA): The stock plunged yesterday amid a high-profile short seller's accusations of overstated earnings.Alibaba (BABA): Its logistics arm reportedly plans to merge its autonomous driving unit with a Chinese ‘Robovan’ startup.Nvidia (NVDA):&nbsp;Faces renewed scrutiny after U.S. lawmakers raised concerns about its past involvement with China’s DeepSeek AI models.Home Depot (HD): Has announced layoffs of roughly 800 workers and mandated a full return to work-from-office.CRISPR Therapeutics (CRSP),&nbsp;Beam Therapeutics (BEAM):&nbsp;Cathie Wood’s ARK Investment Management has bought shares in these gene-editing stocks.Serina Therapeutics (SER): The stock surged in after-hours trading after the FDA cleared its Investigational New Drug (IND) application for a drug to treat advanced Parkinson’s disease.Other tickers trending on Stocktwits at the time of writing included ServiceNow (NOW), SoFi Technologies (SOFI), CrowdStrike Holdings (CRWD), and Novavax (NVAX), among others.&nbsp; Other Catalysts To Watch On the economic front, traders will monitor Initial Jobless Claims and the U.S. Trade Balance data today.And on the earnings radar, investors will also be watching for the quarterly reports from Mastercard (MA), Honeywell (HON), Caterpillar (CAT), and Comcast (CMCSA) before the markets open. After the close, investors will watch earnings from Visa, SAP, KLA, Deckers Brands, and Stryker, among others.For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Climb Ahead Of Apple Earnings: Why META, TSLA, MP, CRML, SER Are On Traders' Radar Today

 Retail sentiment on major ETFs such as SPY and QQQ remains ‘extremely bearish’ on Stocktwits. 

<ul class="summary-bullets"><li>The agency has requested more information regarding an excipient in the formulation of SER-252, the company said.&nbsp;</li><li>The company said that it intends to work with the FDA to address its concerns. &nbsp;</li></ul>Shares of Serina Therapeutics (SER) slumped 7% in the pre-market session on Monday after the company announced that the U.S. Food and Drug Administration (FDA) had placed a clinical hold on its application to initiate clinical trials for its advanced Parkinson’s disease therapy candidate.The agency has requested more information regarding an excipient in the formulation of SER-252, the company said. An excipient is a substance, other than the active pharmaceutical ingredient (API), that is deliberately included in a drug formulation.Serina<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/03/3178999/0/en/Serina-Therapeutics-Provides-Regulatory-Update-on-SER-252-Program.html"> noted</a> that the agency’s feedback does not relate to its active drug substance or its proposed action mechanism.<h2 class="st-heading-2">What Are The Steps Forward?</h2>The company said that it intends to work with the FDA to address its concerns. Serina expects to receive the FDA’s formal clinical-hold letter within 30 days and provide an update once it has aligned with the agency on the next steps.<blockquote>“We appreciate the FDA’s engagement and constructive feedback. We will provide the additional information requested promptly as we continue to move forward in the registrational trial for SER-252.”&nbsp; -Steve Ledger, CEO, Serina Therapeutics.</blockquote>Board Member of Serina and Co-Founder and Executive Chairman of Juvenescence, Greg Bailey, has pledged to continue supporting the company financially and strategically in the initiation of clinical trials for SER-252. The registrational study of SER-252 is designed to evaluate the safety, tolerability, and pharmacokinetics of subcutaneous SER-252 compared to placebo, and will be conducted across sites in the U.S. and Australia.“This update does not change our conviction in Serina’s long-term potential or our belief in SER-252’s ability to meaningfully improve the lives of patients with advanced Parkinson’s disease,” he added.<h2 class="st-heading-2"> How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SER">SER stock</a> stayed within the ‘neutral’ territory over the past 24 hours, while message volume jumped from ‘normal’ to ‘high’ levels.SER stock is down 0.2% this year and approximately 22% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/vertiv-bets-1-billion-on-ai-infrastructure-buys-liquid-cooling-firm-purge-rite/cL2NPfzR3za">Vertiv Bets $1 Billion On AI Infrastructure, Buys Liquid-Cooling Firm PurgeRite</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

Serina Therapeutics Stock Slumps Pre-Market After FDA Places Hold On Application To Initiate Clinical Trials For Experimental Therapy

Serina noted that the agency’s feedback does not relate to its active drug substance or its proposed action mechanism.

Shares of Serina Therapeutics surged 37% in after-hours trading on Monday after the company said the U.S. Food and Drug Administration (FDA) supported advancing its Parkinson’s drug candidate SER-252 (POZ-apomorphine) into a registrational clinical program.The stock ended Monday’s session down 0.2% at $5.64, but surged 37.2% to $7.74 in after-hours trading following the FDA update.The FDA feedback followed a recent Type B meeting and paves the way for Serina to move forward with a streamlined regulatory strategy.“People living with advanced Parkinson’s need more consistent relief from motor fluctuations and our data to date suggest that SER-252 may reliably improve daily function,” CEO Steve Ledger said, adding that the company’s plan is designed to be both rigorous and capital efficient.The proposed program will leverage prior knowledge of apomorphine while incorporating Serina’s POZ-enabled profile. According to the FDA’s feedback, Serina’s first study could be designed as part of its overall registrational trial program, subject to final documentation at the time of IND submission.Serina plans to submit a U.S. IND application in the fourth quarter of 2025 and begin dosing patients in Australia later this year, with the data expected to feed into the global registrational package. U.S. patient enrollment is anticipated to begin in the first quarter of 2026, once the IND is cleared.The planned SER-252-1b study will test the therapy in up to 88 adults with Parkinson’s disease and motor fluctuations, evaluating safety, tolerability, pharmacokinetics, and exploratory efficacy measures, including MDS-UPDRS motor scores.SER-252 is designed to provide continuous dopaminergic stimulation (CDS) via once- or twice-weekly subcutaneous injections, utilizing Enable Injections’ enFuse wearable delivery platform to enhance patient comfort and convenience.&nbsp;Serina believes its POZ drug optimization technology can help stabilize drug levels and reduce side effects compared with traditional therapies.Ledger said the FDA’s response also validated Serina’s broader pipeline ambitions: “The feedback provides early proof-of-principle for our platform, confirming that we can effectively align with the agency’s expectations for the 505(b)(2) NDA pathway.”On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.One user suggested that Serina shares&nbsp;could continue to rise in the next session and said they were already “fully loaded.”<stembedurl>https://stocktwits.com/Santa34/message/626511634</stembedurl>Another user speculated whether Serina’s stock could reach $20 as soon as the next trading session.<stembedurl>https://stocktwits.com/darthttrader/message/626511005</stembedurl><a href="https://stocktwits.com/symbol/SER">Serina’s stock</a> has risen 12.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Serina’s stock (SER) has risen 12.6% so far in 2025. (Photo credit: Getty Images)

Why Did Serina Therapeutics Stock Rocket 37% After The Bell Today?

The FDA backed advancing its Parkinson’s drug candidate SER-252 into a registrational clinical program, a move that retail traders said could fuel further gains.

Shares of Serina Therapeutics, Inc. surged over 15% in pre-market trading on Tuesday, positioning the clinical-stage biotech&nbsp;stock to hit its highest level in over a month.&nbsp;The jump follows Serina’s announcement of a $10 million equity financing agreement with strategic shareholder JuvVentures (UK), aimed at propelling its SER-252 program for advanced Parkinson’s disease into clinical trials.Under the deal, Serina will issue one million shares of common stock at $10 per share, a significant 120% premium to its Nov. 26 closing price and a 110% premium from Monday’s closing price.The financing is structured in two tranches, with the first $5 million tranche already received on Nov. 27, and the second tranche due by Jan. 31, 2025.&nbsp;The funds will support the advancement of SER-252, an investigational therapy developed using Serina’s proprietary drug optimization technology.&nbsp;Designed to deliver continuous dopaminergic stimulation (CDS), SER-252 aims to mitigate levodopa-related motor complications, such as dyskinesia, while increasing “on time” and reducing “off time” in patients with advanced Parkinson’s disease.&nbsp;The therapy integrates a wearable drug delivery platform, which provides long-acting subcutaneous delivery of CDS without causing skin reactions, enhancing both comfort and convenience for patients.<figure class="image"><img style="aspect-ratio:1318/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SET_sentiment_and_message_volume_on_Dec_3_premarket_ebfe4d174b.png" alt="SET sentiment and message volume on Dec 3 premarket.png" width="1318" height="318"><figcaption>SET sentiment and message volume on Dec 3 premarket as of 8:00 am ET | source: Stocktwits</figcaption></figure>Retail investors were quick to rally behind the stock on Stocktwits, where sentiment turned ‘extremely bullish’ before the opening bell, with message volume surging.&nbsp;<stembedurl>https://stocktwits.com/harry925/message/594787799</stembedurl>Still, Serina’s stock remains down over 67% year-to-date,For updates and corrections, email newsroom[at]stocktwits[dot]com.Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-rises-after-upgrade-price-target-hikes/cJ9kq43RhE">Tesla Stock Rises After Massive Price Target Hikes On Trump, AI Factors: Retail’s Charged Up</a>

Under the deal, Serina will issue one million shares of common stock at $10 per share, a 110% premium from Monday’s closing price.

Serina Therapeutics Stock Soars Pre-Market On $10M Equity Deal To Fund Parkinson’s Trials: Retail Sentiment Explodes

The financing is structured in two tranches, with the first $5 million tranche already received on Nov. 27, and the second tranche due by Jan. 31, 2025. 

Serina Therapeutics, Inc. operates as a clinical-stage biotechnology company, which engages in the research and development of polymer technology. Its POZ technology is designed to optimize drug delivery to maximize compliance, therapeutic outcomes, safety, and quality of life for patients. It also offers drugs to treat neurological diseases, cancer, and pain. The company was founded by J. Milton Harris and Michael D. Bentley on March 26, 2024 and is headquartered in Huntsville, AL.

Serina Therapeutics Inc.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $MDB earnings today?

Current Price	$1.77
Prev Close	$1.80
Open	$1.67
Dividend Yield	0.00%
50-Day Moving Average	$2.39
Beta	-0.06
Avg. Volume	3.88M
PE Ratio	-0.30

52-Week High	$7.92
52-Week Low	$1.53
Market Capitalization	$19.41M
EPS (Annual)	-$1.51
Price to Book	-5.97
Revenue Per Employee	$4,307.69

SER
Serina Therapeutics Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest SER News

SERSerina Therapeutics Inc.